RecruitingPulmonary HypertensionInterstitial Lung Disease (ILD)
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
Eligible age
18+ yrs
Accepts
All genders
Locations
26 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
Sponsor: Tempus AI
You may qualify if…
- ✓ 18 years or older at the time of consent
- ✓ A known diagnosis of interstitial lung disease
- ✓ Diffusing capacity for carbon monoxide (DLCO) \<30% predicted, collected within 6 months prior to consent
- ✓ Willing and able to provide informed consent and undergo all study-specific procedures, including echo and RHC, if required
You may not qualify if…
- ✕ A known diagnosis of pulmonary hypertension (including patients prescribed a therapy specifically for pulmonary arterial hypertension (PAH))
- ✕ A RHC was completed within the previous 1 year or ordered and not yet completed at the time of consent
- ✕ LV ejection fraction ≤ 40% on most recent echo or cardiac MRI, if available
- ✕ Unclassifiable Tempus PH ECG risk result after up to 2 ECG acquisitions
- ✕ A contraindication to RHC exists (for example, pregnancy or mechanical right heart valve)
- ✕ Physician decision that if a patient is directed to RHC by the study protocol, the potential risks of RHC outweigh the potential benefits
- ✕ There is a severe concomitant illness limiting life expectancy to less than 6 months (at the discretion of the investigator)
- ✕ There is a medical or social factor that makes the patient a poor candidate for the study and/or unlikely to be able to comply with the study protocol or complete study procedures (at the discretion of the investigator)
Where it's recruiting
Source: ClinicalTrials.gov · NCT06911632 · last updated 2026-08-04